(Q36941829)

17 August 2017

1 reference

title

Aliskiren, the future of renin-angiotensin system blockade? (English)

1 reference

17 August 2017

Uresin Y

1

1 reference

17 August 2017

Mehtar Bozkurt M

series ordinal

2

1 reference

17 August 2017

Sabirli S

series ordinal

3

1 reference

17 August 2017

Ozunal ZG

series ordinal

4

1 reference

17 August 2017

language of work or name

1 reference

1 September 2007

1 reference

Expert Review of Cardiovascular Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

835-849

1 reference

Direct renin inhibition with aliskiren in hypertension and target organ damage

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Renin-angiotensin system and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.5.5.835

21 January 2018

Identifiers

DOI

10.1586/14779072.5.5.835

1 reference

17 August 2017

1 reference